Veracyte, Inc. (VCYT): Price and Financial Metrics
VCYT Stock Summary
- With a price/sales ratio of 33.4, Veracyte Inc has a higher such ratio than 92.75% of stocks in our set.
- VCYT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 9.14% of US stocks.
- Over the past twelve months, VCYT has reported earnings growth of 190.89%, putting it ahead of 92.28% of US stocks in our set.
- Stocks that are quantitatively similar to VCYT, based on their financial statements, market capitalization, and price volatility, are REFR, CUTR, ECOR, WEI, and EKSO.
- VCYT's SEC filings can be seen here. And to visit Veracyte Inc's official web site, go to www.veracyte.com.
VCYT Stock Price Chart Interactive Chart >
VCYT Price/Volume Stats
|Current price||$58.06||52-week high||$86.03|
|Prev. close||$58.56||52-week low||$13.90|
|Day high||$61.87||Avg. volume||948,202|
|50-day MA||$58.88||Dividend yield||N/A|
|200-day MA||$40.95||Market Cap||3.89B|
Veracyte, Inc. (VCYT) Company Bio
Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.
VCYT Latest News Stream
|Loading, please wait...|
VCYT Latest Social Stream
View Full VCYT Social Stream
Latest VCYT News From Around the Web
Below are the latest news stories about Veracyte Inc that investors may wish to consider to help them evaluate VCYT as an investment opportunity.
Veracyte, Inc. (VCYT) Q4 2020 Earnings Conference Call February 17, 2021 16:30 ET Company Participants Tracy Morris - Vice President, Corporate Communications and Investor Relations Bonnie Anderson - Chairman and Chief Executive Officer Keith Kennedy - Chief Operating Officer and Chief Financial Officer Conference Call Participants Puneet Souda - SVB...
Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
The following slide deck was published by Veracyte, Inc. in conjunction with their 2020 Q4 earnings call....
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which missed the estimate of ($0.11). Revenue of $34,536,000 up by 16.17% year over year, which beat the estimate of $31,930,000. Guidance Veracyte Sees FY21 Sales $190M-$200M Vs. $151.18M Est. Conference Call Details Date: Feb 17, 2021 Time: 05:30 PM View more earnings on VCYT ET Webcast URL: https://edge.media-server.com/mmc/p/p7geixt9 Price Action 52-week high: $86.03 Company's 52-week low was at $13.90 Price action over last quarter: Up 93.62% Company Profile Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against dise...
VCYT Price Returns
Continue Researching VCYTWant to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!